{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:59Z","timestamp":1793643179033,"version":"4.5.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113361","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T06:27:44Z","timestamp":1729146464000},"page":"113361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"P2","title":["Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K\/AKT\/PD-L1 axis"],"prefix":"10.1016","volume":"143","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4478-8440","authenticated-orcid":false,"given":"Yaya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113361_b0005","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113361_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 5","key":"10.1016\/j.intimp.2024.113361_b0015","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.113361_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","article-title":"Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives","volume":"10","author":"Chiappella","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.intimp.2024.113361_b0025","doi-asserted-by":"crossref","first-page":"FSO322","DOI":"10.4155\/fsoa-2018-0049","article-title":"Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"4","author":"Galaznik","year":"2018","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.intimp.2024.113361_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.intimp.2024.113361_b0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2024.113361_b0040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2024.113361_b0045","first-page":"3321","article-title":"Over-activated PD-1\/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2024.113361_b0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113361_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061326","article-title":"Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1\/PD-L1 Pathway in Diffuse Large B-cell Lymphoma","volume":"20","author":"Song","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113361_b0060","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5037","article-title":"SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO\/STAT3 axis","volume":"48","author":"Qin","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.intimp.2024.113361_b0065","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1541-7786.MCR-18-0409","article-title":"SPHK1 is a novel target of metformin in ovarian cancer","volume":"17","author":"Hart","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113361_b0070","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M085191","article-title":"Sphingosine kinase 1 activation by estrogen receptor alpha36 contributes to tamoxifen resistance in breast cancer","volume":"59","author":"Maczis","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.intimp.2024.113361_b0075","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/138945008785132402","article-title":"Targeting SphK1 as a new strategy against cancer","volume":"9","author":"Shida","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.intimp.2024.113361_b0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113361_b0085","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41375-019-0478-9","article-title":"Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma","volume":"33","author":"Lupino","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2024.113361_b0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biopha.2011.02.004","article-title":"Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K\/AKT\/NF-small ka, CyrillicB pathway","volume":"65","author":"Fu","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113361_b0095","article-title":"PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K\/AKT pathway","author":"Hong","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.intimp.2024.113361_b0100","doi-asserted-by":"crossref","first-page":"8861766","DOI":"10.1155\/2021\/8861766","article-title":"Increased SPHK1 and HAS2 expressions correlate to poor prognosis in pancreatic cancer","volume":"2021","author":"Yu","year":"2021","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.intimp.2024.113361_b0105","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.18632\/oncotarget.3178","article-title":"A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties","volume":"6","author":"Pitman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.113361_b0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.29362","article-title":"Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer","volume":"137","author":"Lee","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2024.113361_b0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.intimp.2024.113361_b0120","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.113361_b0125","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2016.90","article-title":"Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1\/Akt\/NF-kappaB signaling","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.113361_b0130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm0802-787","article-title":"Protect the killer: CTLs need defenses against the tumor","volume":"8","author":"Freeman","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113361_b0135","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/cancers11040462","article-title":"Ntrk1 promotes resistance to PD-1 checkpoint blockade in mesenchymal Kras\/p53 mutant lung cancer","volume":"11","author":"Konen","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.113361_b0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41419-019-1886-5","article-title":"LncRNA SNHG14\/miR-5590-3p\/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1\/PD-L1 checkpoint","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.113361_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells9041030","article-title":"Sphingosine kinase blockade leads to increased natural killer T cell responses to mantle cell lymphoma","volume":"9","author":"Lee","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2024.113361_b0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.intimp.2014.08.026","article-title":"Collagenases in an ether extract of bacterial metabolites used as an immunostimulator induces TNF-alpha and IFN-gamma","volume":"23","author":"Singh","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113361_b0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2003533","article-title":"Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma","volume":"10","author":"Stirm","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.113361_b0160","first-page":"3883","article-title":"HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K\/Akt\/NF-kappaB signaling pathway","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2024.113361_b0165","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2024.113361_b0170","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6863240","article-title":"ATXN2-mediated PI3K\/AKT activation confers gastric cancer chemoresistance and attenuates CD8+ T cell cytotoxicity","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2024.113361_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106759","article-title":"Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin","volume":"86","author":"Kongtawelert","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113361_b0180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/path.4879","article-title":"Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3","volume":"242","author":"Lee","year":"2017","journal-title":"J. Pathol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924018836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924018836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:31:04Z","timestamp":1736303464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924018836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S1567576924018836"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113361","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K\/AKT\/PD-L1 axis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113361"}}